Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting
Purpose To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens. Methods ER analyses were conducted using pooled NS...
Uloženo v:
| Vydáno v: | Cancer chemotherapy and pharmacology Ročník 84; číslo 6; s. 1257 - 1267 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Berlin/Heidelberg
Springer Berlin Heidelberg
01.12.2019
Springer Nature B.V |
| Témata: | |
| ISSN: | 0344-5704, 1432-0843, 1432-0843 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Purpose
To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens.
Methods
ER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, and NCT02302807, respectively). Objective response rate, overall survival, and adverse events were evaluated vs pharmacokinetic (PK) metrics. Population PK-simulated exposures for regimens of 840 mg every 2 weeks (q2w) and 1680 mg every 4 weeks (q4w) were compared with the approved regimen of 1200 mg every 3 weeks (q3w) and the maximum assessed dose (MAD; 20 mg/kg q3w). Phase 3 IMpassion130 (NCT02425891) data were used to validate the PK simulations for 840 mg q2w. Observed safety data were evaluated by exposure and body weight subgroups.
Results
No significant ER relationships were observed for safety or efficacy. Predicted exposures for 840 mg q2w and 1680 mg q4w were comparable to 1200 mg q3w and the MAD and consistent with observed PK data from IMpassion130. Observed safety was similar between patients with a
C
max
above and below the predicted
C
max
for 1680 mg q4w and between patients in the lowest and upper 3 body weight quartiles.
Conclusion
Atezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility. |
|---|---|
| AbstractList | To determine the exposure-response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens.PURPOSETo determine the exposure-response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens.ER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, and NCT02302807, respectively). Objective response rate, overall survival, and adverse events were evaluated vs pharmacokinetic (PK) metrics. Population PK-simulated exposures for regimens of 840 mg every 2 weeks (q2w) and 1680 mg every 4 weeks (q4w) were compared with the approved regimen of 1200 mg every 3 weeks (q3w) and the maximum assessed dose (MAD; 20 mg/kg q3w). Phase 3 IMpassion130 (NCT02425891) data were used to validate the PK simulations for 840 mg q2w. Observed safety data were evaluated by exposure and body weight subgroups.METHODSER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, and NCT02302807, respectively). Objective response rate, overall survival, and adverse events were evaluated vs pharmacokinetic (PK) metrics. Population PK-simulated exposures for regimens of 840 mg every 2 weeks (q2w) and 1680 mg every 4 weeks (q4w) were compared with the approved regimen of 1200 mg every 3 weeks (q3w) and the maximum assessed dose (MAD; 20 mg/kg q3w). Phase 3 IMpassion130 (NCT02425891) data were used to validate the PK simulations for 840 mg q2w. Observed safety data were evaluated by exposure and body weight subgroups.No significant ER relationships were observed for safety or efficacy. Predicted exposures for 840 mg q2w and 1680 mg q4w were comparable to 1200 mg q3w and the MAD and consistent with observed PK data from IMpassion130. Observed safety was similar between patients with a Cmax above and below the predicted Cmax for 1680 mg q4w and between patients in the lowest and upper 3 body weight quartiles.RESULTSNo significant ER relationships were observed for safety or efficacy. Predicted exposures for 840 mg q2w and 1680 mg q4w were comparable to 1200 mg q3w and the MAD and consistent with observed PK data from IMpassion130. Observed safety was similar between patients with a Cmax above and below the predicted Cmax for 1680 mg q4w and between patients in the lowest and upper 3 body weight quartiles.Atezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility.CONCLUSIONAtezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility. PurposeTo determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens.MethodsER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, and NCT02302807, respectively). Objective response rate, overall survival, and adverse events were evaluated vs pharmacokinetic (PK) metrics. Population PK-simulated exposures for regimens of 840 mg every 2 weeks (q2w) and 1680 mg every 4 weeks (q4w) were compared with the approved regimen of 1200 mg every 3 weeks (q3w) and the maximum assessed dose (MAD; 20 mg/kg q3w). Phase 3 IMpassion130 (NCT02425891) data were used to validate the PK simulations for 840 mg q2w. Observed safety data were evaluated by exposure and body weight subgroups.ResultsNo significant ER relationships were observed for safety or efficacy. Predicted exposures for 840 mg q2w and 1680 mg q4w were comparable to 1200 mg q3w and the MAD and consistent with observed PK data from IMpassion130. Observed safety was similar between patients with a Cmax above and below the predicted Cmax for 1680 mg q4w and between patients in the lowest and upper 3 body weight quartiles.ConclusionAtezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility. To determine the exposure-response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens. ER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, and NCT02302807, respectively). Objective response rate, overall survival, and adverse events were evaluated vs pharmacokinetic (PK) metrics. Population PK-simulated exposures for regimens of 840 mg every 2 weeks (q2w) and 1680 mg every 4 weeks (q4w) were compared with the approved regimen of 1200 mg every 3 weeks (q3w) and the maximum assessed dose (MAD; 20 mg/kg q3w). Phase 3 IMpassion130 (NCT02425891) data were used to validate the PK simulations for 840 mg q2w. Observed safety data were evaluated by exposure and body weight subgroups. No significant ER relationships were observed for safety or efficacy. Predicted exposures for 840 mg q2w and 1680 mg q4w were comparable to 1200 mg q3w and the MAD and consistent with observed PK data from IMpassion130. Observed safety was similar between patients with a C above and below the predicted C for 1680 mg q4w and between patients in the lowest and upper 3 body weight quartiles. Atezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility. PURPOSE: To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens. METHODS: ER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, and NCT02302807, respectively). Objective response rate, overall survival, and adverse events were evaluated vs pharmacokinetic (PK) metrics. Population PK-simulated exposures for regimens of 840 mg every 2 weeks (q2w) and 1680 mg every 4 weeks (q4w) were compared with the approved regimen of 1200 mg every 3 weeks (q3w) and the maximum assessed dose (MAD; 20 mg/kg q3w). Phase 3 IMpassion130 (NCT02425891) data were used to validate the PK simulations for 840 mg q2w. Observed safety data were evaluated by exposure and body weight subgroups. RESULTS: No significant ER relationships were observed for safety or efficacy. Predicted exposures for 840 mg q2w and 1680 mg q4w were comparable to 1200 mg q3w and the MAD and consistent with observed PK data from IMpassion130. Observed safety was similar between patients with a Cₘₐₓ above and below the predicted Cₘₐₓ for 1680 mg q4w and between patients in the lowest and upper 3 body weight quartiles. CONCLUSION: Atezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility. Purpose To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) and to identify alternative dosing regimens. Methods ER analyses were conducted using pooled NSCLC and UC data from phase 1 and 3 studies (PCD4989g, OAK, IMvigor211; ClinicalTrials.gov IDs, NCT01375842, NCT02008227, and NCT02302807, respectively). Objective response rate, overall survival, and adverse events were evaluated vs pharmacokinetic (PK) metrics. Population PK-simulated exposures for regimens of 840 mg every 2 weeks (q2w) and 1680 mg every 4 weeks (q4w) were compared with the approved regimen of 1200 mg every 3 weeks (q3w) and the maximum assessed dose (MAD; 20 mg/kg q3w). Phase 3 IMpassion130 (NCT02425891) data were used to validate the PK simulations for 840 mg q2w. Observed safety data were evaluated by exposure and body weight subgroups. Results No significant ER relationships were observed for safety or efficacy. Predicted exposures for 840 mg q2w and 1680 mg q4w were comparable to 1200 mg q3w and the MAD and consistent with observed PK data from IMpassion130. Observed safety was similar between patients with a C max above and below the predicted C max for 1680 mg q4w and between patients in the lowest and upper 3 body weight quartiles. Conclusion Atezolizumab regimens of 840 mg q2w and 1680 mg q4w are expected to have comparable efficacy and safety as the approved regimen of 1200 mg q3w, supporting their interchangeable use and offering patients greater flexibility. |
| Author | Girish, Sandhya Patel, Hina Winter, Helen R. Jin, Jin Y. Morrissey, Kari M. Zhang, Rong Marchand, Mathilde Phyllis Chan, H. Mecke, Almut Bruno, René Wu, Benjamin |
| Author_xml | – sequence: 1 givenname: Kari M. orcidid: 0000-0001-9025-4036 surname: Morrissey fullname: Morrissey, Kari M. email: morrissey.kari@gene.com organization: Clinical Pharmacology, Genentech, Inc – sequence: 2 givenname: Mathilde surname: Marchand fullname: Marchand, Mathilde organization: Certara Strategic Consulting, Certara – sequence: 3 givenname: Hina surname: Patel fullname: Patel, Hina organization: Safety Science Oncology, Genentech Inc – sequence: 4 givenname: Rong surname: Zhang fullname: Zhang, Rong organization: Clinical Pharmacology, Genentech, Inc – sequence: 5 givenname: Benjamin surname: Wu fullname: Wu, Benjamin organization: Clinical Pharmacology, Genentech, Inc – sequence: 6 givenname: H. surname: Phyllis Chan fullname: Phyllis Chan, H. organization: Clinical Pharmacology, Genentech, Inc – sequence: 7 givenname: Almut orcidid: 0000-0002-9183-0047 surname: Mecke fullname: Mecke, Almut organization: Biostatistics, F. Hoffmann-La Roche, Ltd – sequence: 8 givenname: Sandhya surname: Girish fullname: Girish, Sandhya organization: Clinical Pharmacology, Genentech, Inc – sequence: 9 givenname: Jin Y. surname: Jin fullname: Jin, Jin Y. organization: Clinical Pharmacology, Genentech, Inc – sequence: 10 givenname: Helen R. surname: Winter fullname: Winter, Helen R. organization: Clinical Pharmacology, Genentech, Inc, Seattle Genetics – sequence: 11 givenname: René orcidid: 0000-0003-0200-039X surname: Bruno fullname: Bruno, René organization: Clinical Pharmacology, Genentech/Roche |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31542806$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkktv1TAUhC1URG8Lf4AFssSGTYpfiRMWSFUFFKkSG1hbvs5J6uLYwXauSn89Tm_Lo4uy8Vn4m9HYZ47QgQ8eEHpJyQklRL5NhLCWVIR2FeFdLar2CdpQwVlFWsEP0IZwIapaEnGIjlK6IoQIyvkzdMhpLYq02aDrU5chep3tDnAfkvUjjjDaCXzCQ4hYZ7gJzt4sk96-w9pjuNbT7ACHAU-hB1dZX7gJetzHZcQ97MCFuegzth7nS8BzSHnS8Tvk1T1BXudz9HTQLsGLu3mMvn388PXsvLr48unz2elFZWoic0nfy6GjtG063QkwHWmppH0jGKG9ND2FFoZ6MKJmtFwJY6RhsoztYHTX1_wYvd_7zsu2hDQlV9ROzdGWSD9V0Fb9e-PtpRrDTjUtIw1pisGbO4MYfiyQsppsMuCc9hCWpMpf8rZuyvlflLGuoVwyJgv6-gF6FZayB3dLCVl3olsNX_0d_nfq-_0VoN0DJoaUIgzK2FyWGda3WKcoUWtV1L4qqlRF3VZFtUXKHkjv3R8V8b0oFdiPEP_EfkT1C7tf0t8 |
| CitedBy_id | crossref_primary_10_1158_1078_0432_CCR_19_0287 crossref_primary_10_1111_bcp_14662 crossref_primary_10_1111_cts_70077 crossref_primary_10_1007_s40265_021_01654_3 crossref_primary_10_3390_vaccines8040632 crossref_primary_10_1136_jitc_2020_002266 crossref_primary_10_1002_jcph_2203 crossref_primary_10_1016_S0140_6736_25_00405_2 crossref_primary_10_1007_s00228_020_03054_0 crossref_primary_10_1016_j_annonc_2023_05_009 crossref_primary_10_1111_cts_13127 crossref_primary_10_1002_psp4_13063 crossref_primary_10_3390_cancers15153980 crossref_primary_10_1016_j_jtho_2022_07_008 crossref_primary_10_1208_s12248_023_00838_x crossref_primary_10_1177_1078155220960211 crossref_primary_10_1002_cpdd_936 crossref_primary_10_1186_s13045_021_01182_3 crossref_primary_10_1002_cpt_3133 crossref_primary_10_1016_j_annonc_2023_08_008 crossref_primary_10_3390_ijms241411694 crossref_primary_10_1002_cpt_1951 crossref_primary_10_1016_j_clinthera_2024_08_020 crossref_primary_10_1002_cpt_1953 crossref_primary_10_1111_cts_70223 crossref_primary_10_1111_cts_13312 crossref_primary_10_1007_s00280_023_04541_8 crossref_primary_10_1016_j_critrevonc_2020_103033 crossref_primary_10_1177_10600280231187421 crossref_primary_10_1016_j_nucmedbio_2021_05_004 crossref_primary_10_1016_j_intimp_2021_107703 crossref_primary_10_1097_PPO_0000000000000461 crossref_primary_10_1016_S1470_2045_22_00274_1 crossref_primary_10_1007_s40262_019_00837_2 crossref_primary_10_1158_1078_0432_CCR_21_3149 crossref_primary_10_1007_s40273_025_01535_7 crossref_primary_10_1159_000515817 crossref_primary_10_1016_j_jtocrr_2024_100683 crossref_primary_10_1158_1078_0432_CCR_20_0298 crossref_primary_10_1002_cpt_3345 crossref_primary_10_1208_s12248_022_00710_4 crossref_primary_10_1016_j_compbiomed_2024_108961 crossref_primary_10_1007_s00280_024_04643_x crossref_primary_10_1158_1078_0432_CCR_23_0798 crossref_primary_10_1186_s40425_019_0791_x crossref_primary_10_1016_j_currproblcancer_2025_101204 crossref_primary_10_1111_bcp_14369 crossref_primary_10_1007_s40262_022_01111_8 crossref_primary_10_1111_cts_13149 crossref_primary_10_3389_fonc_2020_01193 crossref_primary_10_1016_j_puhip_2024_100557 crossref_primary_10_1007_s00280_021_04276_4 crossref_primary_10_1002_prp2_757 crossref_primary_10_1016_j_critrevonc_2023_103913 crossref_primary_10_1111_cts_70125 crossref_primary_10_1007_s00280_019_03971_7 crossref_primary_10_1371_journal_pone_0309778 crossref_primary_10_1007_s11523_023_00958_6 crossref_primary_10_3389_fonc_2022_906251 crossref_primary_10_1007_s10637_024_01498_0 crossref_primary_10_1080_20415990_2025_2506980 crossref_primary_10_1016_j_addr_2022_114112 crossref_primary_10_1016_j_ejca_2023_113349 crossref_primary_10_2217_fon_2023_0282 crossref_primary_10_1002_prp2_685 crossref_primary_10_1158_1078_0432_CCR_19_3408 crossref_primary_10_1007_s00228_020_02980_3 crossref_primary_10_1016_j_cyto_2025_156979 crossref_primary_10_3389_fphar_2022_974423 |
| Cites_doi | 10.1093/annonc/mdz037 10.1158/1078-0432.CCR-17-3662 10.1158/1078-0432.CCR-12-1362 10.1200/JCO.2018.36.15_suppl.3062 10.1002/cpt.587 10.1038/nature13904 10.1186/s40425-017-0242-5 10.1016/j.ejca.2018.06.031 10.1038/clpt.2014.4 10.1016/S1542-3565(04)00238-1 10.1016/S0140-6736(17)33297-X 10.1007/s10928-017-9528-y 10.1038/clpt.2014.24 10.1002/psp4.12143 10.1016/S0140-6736(16)32517-X 10.1093/annonc/mdx235 10.1056/NEJMoa1809615 10.1002/cpt.656 10.1001/jamaoncol.2017.5440 10.1200/jco.2018.36.5_suppl.62 10.1038/nature14011 10.1002/cpt.628 10.1038/nbt1303 10.1016/j.immuni.2013.07.012 10.1007/s10637-016-0371-6 10.1177/0091270012445206 10.1080/19420862.2015.1136043 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2019 Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2019 – notice: Cancer Chemotherapy and Pharmacology is a copyright of Springer, (2019). All Rights Reserved. © 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM |
| DOI | 10.1007/s00280-019-03954-8 |
| DatabaseName | Springer Nature Link CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic Oncogenes and Growth Factors Abstracts MEDLINE AGRICOLA |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1432-0843 |
| EndPage | 1267 |
| ExternalDocumentID | PMC6820606 31542806 10_1007_s00280_019_03954_8 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: F. Hoffmann-La Roche Ltd – fundername: ; |
| GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACUDM ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 Y6R YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFFHD AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY CGR CUY CVF ECM EIF NPM 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c507t-57d7f911869a94ec908171d64201d7cd1e8ef5fc45210814cc7c274ccbfca9d53 |
| IEDL.DBID | 8C1 |
| ISICitedReferencesCount | 74 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000497443600012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0344-5704 1432-0843 |
| IngestDate | Tue Nov 04 01:56:21 EST 2025 Thu Sep 04 20:21:01 EDT 2025 Fri Sep 05 13:23:51 EDT 2025 Sat Nov 08 22:12:17 EST 2025 Wed Feb 19 02:30:49 EST 2025 Sat Nov 29 04:45:35 EST 2025 Tue Nov 18 21:20:31 EST 2025 Fri Feb 21 02:33:15 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | PD-L1 Population pharmacokinetics Exposure–response Atezolizumab |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c507t-57d7f911869a94ec908171d64201d7cd1e8ef5fc45210814cc7c274ccbfca9d53 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-9183-0047 0000-0001-9025-4036 0000-0003-0200-039X |
| OpenAccessLink | https://link.springer.com/10.1007/s00280-019-03954-8 |
| PMID | 31542806 |
| PQID | 2294759493 |
| PQPubID | 48447 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6820606 proquest_miscellaneous_3153856153 proquest_miscellaneous_2296137227 proquest_journals_2294759493 pubmed_primary_31542806 crossref_citationtrail_10_1007_s00280_019_03954_8 crossref_primary_10_1007_s00280_019_03954_8 springer_journals_10_1007_s00280_019_03954_8 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-12-01 |
| PublicationDateYYYYMMDD | 2019-12-01 |
| PublicationDate_xml | – month: 12 year: 2019 text: 2019-12-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Berlin/Heidelberg |
| PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
| PublicationTitle | Cancer chemotherapy and pharmacology |
| PublicationTitleAbbrev | Cancer Chemother Pharmacol |
| PublicationTitleAlternate | Cancer Chemother Pharmacol |
| PublicationYear | 2019 |
| Publisher | Springer Berlin Heidelberg Springer Nature B.V |
| Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
| References | Stroh, Winter, Marchand, Claret, Eppler, Ruppel, Abidoye, Teng, Lin, Dayog, Bruno, Jin, Girish (CR6) 2017; 102 Horn, Gettinger, Gordon, Herbst, Gandhi, Felip, Sequist, Spigel, Antonia, Balmanoukian, Cassier, Liu, Kowanetz, O’Hear, Fassò, Grossman, Sandler, Soria (CR12) 2018; 101 Li, Yu, Liu, Liu, Subramaniam, Zhao, Blumenthal, Turner, Li, Ahamadi, de Greef, Chatterjee, Kondic, Stone, Booth, Keegan, Rahman, Wang (CR20) 2017; 44 Powles, Duran, van der Heijden, Loriot, Vogelzang, De Giorgi, Oudard, Retz, Castellano, Bamias, Flechon, Gravis, Hussain, Takano, Leng, Kadel, Banchereau, Hegde, Mariathasan, Cui, Shen, Derleth, Green, Ravaud (CR14) 2018; 391 Chen, Irving, Hodi (CR2) 2012; 18 Powles, Eder, Fine, Braiteh, Loriot, Cruz, Bellmunt, Burris, Petrylak, Teng, Shen, Boyd, Hegde, Chen, Vogelzang (CR10) 2014; 515 Bruno, Mercier, Claret (CR23) 2014; 95 Bruno, Claret, Wu, Jin, Winter, Cui, Derleth, Shen, Girish, Rosenberg, Powles (CR25) 2018; 36 CR31 CR30 Deng, Bumbaca, Pastuskovas, Boswell, West, Cowan, Chiu, McBride, Johnson, Xin, Koeppen, Leabman, Iyer (CR7) 2016; 8 Schmid, Adams, Rugo, Schneeweiss, Barrios, Iwata, Dieras, Hegg, Im, Shaw Wright, Henschel, Molinero, Chui, Funke, Husain, Winer, Loi, Emens, Investigators (CR16) 2018; 379 Bajaj, Wang, Agrawal, Gupta, Roy, Feng (CR19) 2017; 6 Rittmeyer, Barlesi, Waterkamp, Park, Ciardiello, von Pawel, Gadgeel, Hida, Kowalski, Dols, Cortinovis, Leach, Polikoff, Barrios, Kabbinavar, Frontera, De Marinis, Turna, Lee, Ballinger, Kowanetz, He, Chen, Sandler, Gandara, Group (CR13) 2017; 389 Lala, Li, Sinha, de Alwis, Chartash, Jain (CR32) 2018; 36 Mizugaki, Yamamoto, Murakami, Kenmotsu, Fujiwara, Ishida, Kawakami, Takahashi (CR15) 2016; 34 Petrylak, Powles, Bellmunt, Braiteh, Loriot, Morales-Barrera, Burris, Kim, Ding, Kaiser, Fasso, O’Hear, Vogelzang (CR11) 2018; 4 Yang, Zhao, Garnett, Rahman, Gobburu, Pierce, Schechter, Summers, Keegan, Booth, Wang (CR17) 2013; 53 CR4 Zhao, Suryawanshi, Hruska, Feng, Wang, Shen, Vezina, McHenry, Waxman, Achanta, Bello, Roy, Agrawal (CR33) 2017; 28 CR5 Bi, Liu, Furmanski, Zhao, Yu, Osgood, Ward, Keegan, Booth, Rahman, Wang (CR8) 2019; 30 CR9 CR27 CR26 Liu, Yu, Li, Liu, Xu, Song, Liu, Zhao, Xu, Maher, Booth, Kim, Rahman, Wang (CR21) 2017; 101 Wang, Booth, Rahman, Kim, Huang, Zineh (CR22) 2017; 101 Freshwater, Kondic, Ahamadi, Li, de Greef, de Alwis, Stone (CR34) 2017; 5 Herbst, Soria, Kowanetz, Fine, Hamid, Gordon, Sosman, McDermott, Powderly, Gettinger, Kohrt, Horn, Lawrence, Rost, Leabman, Xiao, Mokatrin, Koeppen, Hegde, Mellman, Chen, Hodi (CR3) 2014; 515 Claret, Jin, Ferte, Winter, Girish, Stroh, He, Ballinger, Sandler, Joshi, Rittmeyer, Gandara, Soria, Bruno (CR24) 2018; 24 Hanauer, Wagner, Bala, Mayer, Travers, Diamond, Olson, Bao, Rutgeerts (CR28) 2004; 2 Shankar, Pendley, Stein (CR29) 2007; 25 Wang, Song, Schrieber, Liu, Xu, Blumenthal, Amiri Kordestani, Cortazar, Ibrahim, Justice, Wang, Tang, Booth, Mehrotra, Rahman (CR18) 2014; 95 Chen, Mellman (CR1) 2013; 39 J Yang (3954_CR17) 2013; 53 R Bruno (3954_CR23) 2014; 95 3954_CR31 3954_CR30 T Freshwater (3954_CR34) 2017; 5 H Mizugaki (3954_CR15) 2016; 34 T Powles (3954_CR10) 2014; 515 R Bruno (3954_CR25) 2018; 36 J Wang (3954_CR18) 2014; 95 G Shankar (3954_CR29) 2007; 25 DS Chen (3954_CR2) 2012; 18 A Rittmeyer (3954_CR13) 2017; 389 SB Hanauer (3954_CR28) 2004; 2 DP Petrylak (3954_CR11) 2018; 4 X Zhao (3954_CR33) 2017; 28 DS Chen (3954_CR1) 2013; 39 P Schmid (3954_CR16) 2018; 379 3954_CR9 3954_CR26 Y Bi (3954_CR8) 2019; 30 T Powles (3954_CR14) 2018; 391 3954_CR27 G Bajaj (3954_CR19) 2017; 6 Y Wang (3954_CR22) 2017; 101 M Stroh (3954_CR6) 2017; 102 L Claret (3954_CR24) 2018; 24 RS Herbst (3954_CR3) 2014; 515 L Horn (3954_CR12) 2018; 101 M Lala (3954_CR32) 2018; 36 3954_CR4 3954_CR5 R Deng (3954_CR7) 2016; 8 C Liu (3954_CR21) 2017; 101 H Li (3954_CR20) 2017; 44 31630223 - Cancer Chemother Pharmacol. 2019 Dec;84(6):1153-1155 |
| References_xml | – volume: 30 start-page: 644 issue: 4 year: 2019 end-page: 651 ident: CR8 article-title: Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective publication-title: Ann Oncol doi: 10.1093/annonc/mdz037 – volume: 24 start-page: 3292 issue: 14 year: 2018 end-page: 3298 ident: CR24 article-title: A model of overall survival predicts treatment outcomes with atezolizumab versus chemotherapy in non-small cell lung cancer based on early tumor kinetics publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-3662 – volume: 18 start-page: 6580 issue: 24 year: 2012 end-page: 6587 ident: CR2 article-title: Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-1362 – volume: 36 start-page: 3062 issue: 15 year: 2018 ident: CR32 article-title: A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure–response (E–R) evaluation using modeling and simulation publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.3062 – ident: CR4 – ident: CR30 – volume: 102 start-page: 305 issue: 2 year: 2017 end-page: 312 ident: CR6 article-title: Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.587 – volume: 515 start-page: 558 issue: 7528 year: 2014 end-page: 562 ident: CR10 article-title: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer publication-title: Nature doi: 10.1038/nature13904 – volume: 5 start-page: 43 year: 2017 ident: CR34 article-title: Evaluation of dosing strategy for pembrolizumab for oncology indications publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0242-5 – volume: 101 start-page: 201 year: 2018 end-page: 209 ident: CR12 article-title: Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.06.031 – volume: 95 start-page: 386 issue: 4 year: 2014 end-page: 393 ident: CR23 article-title: Evaluation of tumor size response metrics to predict survival in oncology clinical trials publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.4 – volume: 2 start-page: 542 issue: 7 year: 2004 end-page: 553 ident: CR28 article-title: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn’s disease publication-title: Clin Gastroenterol Hepatol doi: 10.1016/S1542-3565(04)00238-1 – ident: CR27 – volume: 391 start-page: 748 issue: 10122 year: 2018 end-page: 757 ident: CR14 article-title: Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial publication-title: Lancet (Lond, Engl) doi: 10.1016/S0140-6736(17)33297-X – volume: 44 start-page: 403 issue: 5 year: 2017 end-page: 414 ident: CR20 article-title: Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-017-9528-y – volume: 95 start-page: 558 issue: 5 year: 2014 end-page: 564 ident: CR18 article-title: Exposure–response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.24 – volume: 6 start-page: 58 issue: 1 year: 2017 end-page: 66 ident: CR19 article-title: Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1002/psp4.12143 – volume: 389 start-page: 255 issue: 10066 year: 2017 end-page: 265 ident: CR13 article-title: Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial publication-title: Lancet (Lond, Engl) doi: 10.1016/S0140-6736(16)32517-X – volume: 28 start-page: 2002 issue: 8 year: 2017 end-page: 2008 ident: CR33 article-title: Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors publication-title: Ann Oncol doi: 10.1093/annonc/mdx235 – volume: 379 start-page: 2108 issue: 22 year: 2018 end-page: 2121 ident: CR16 article-title: Atezolizumab and Nab-paclitaxel in advanced triple-negative breast cancer publication-title: N Eng J Med doi: 10.1056/NEJMoa1809615 – volume: 101 start-page: 657 issue: 5 year: 2017 end-page: 666 ident: CR21 article-title: Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.656 – volume: 4 start-page: 537 issue: 4 year: 2018 end-page: 544 ident: CR11 article-title: Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: long-term outcomes from a phase 1 study publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.5440 – volume: 36 start-page: 62 issue: 5_Suppl year: 2018 ident: CR25 article-title: A tumor growth rate/overall survival model for atezolizumab as an early predictor of OS in patients with first or second line metastatic urothelial carcinoma publication-title: J Clin Oncol doi: 10.1200/jco.2018.36.5_suppl.62 – ident: CR31 – ident: CR9 – volume: 515 start-page: 563 issue: 7528 year: 2014 end-page: 567 ident: CR3 article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients publication-title: Nature doi: 10.1038/nature14011 – volume: 101 start-page: 582 issue: 5 year: 2017 end-page: 584 ident: CR22 article-title: Toward greater insights on pharmacokinetics and exposure–response relationships for therapeutic biologics in oncology drug development publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.628 – ident: CR5 – volume: 25 start-page: 555 issue: 5 year: 2007 end-page: 561 ident: CR29 article-title: A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs publication-title: Nat Biotechnol doi: 10.1038/nbt1303 – volume: 39 start-page: 1 issue: 1 year: 2013 end-page: 10 ident: CR1 article-title: Oncology meets immunology: the cancer-immunity cycle publication-title: Immunity doi: 10.1016/j.immuni.2013.07.012 – ident: CR26 – volume: 34 start-page: 596 issue: 5 year: 2016 end-page: 603 ident: CR15 article-title: Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors publication-title: Invest New Drugs doi: 10.1007/s10637-016-0371-6 – volume: 53 start-page: 160 issue: 2 year: 2013 end-page: 166 ident: CR17 article-title: The combination of exposure–response and case–control analyses in regulatory decision making publication-title: J Clin Pharmacol doi: 10.1177/0091270012445206 – volume: 8 start-page: 593 issue: 3 year: 2016 end-page: 603 ident: CR7 article-title: Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor publication-title: MAbs doi: 10.1080/19420862.2015.1136043 – ident: 3954_CR9 – volume: 28 start-page: 2002 issue: 8 year: 2017 ident: 3954_CR33 publication-title: Ann Oncol doi: 10.1093/annonc/mdx235 – volume: 39 start-page: 1 issue: 1 year: 2013 ident: 3954_CR1 publication-title: Immunity doi: 10.1016/j.immuni.2013.07.012 – volume: 4 start-page: 537 issue: 4 year: 2018 ident: 3954_CR11 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2017.5440 – volume: 34 start-page: 596 issue: 5 year: 2016 ident: 3954_CR15 publication-title: Invest New Drugs doi: 10.1007/s10637-016-0371-6 – volume: 101 start-page: 657 issue: 5 year: 2017 ident: 3954_CR21 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.656 – volume: 102 start-page: 305 issue: 2 year: 2017 ident: 3954_CR6 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.587 – volume: 25 start-page: 555 issue: 5 year: 2007 ident: 3954_CR29 publication-title: Nat Biotechnol doi: 10.1038/nbt1303 – volume: 515 start-page: 558 issue: 7528 year: 2014 ident: 3954_CR10 publication-title: Nature doi: 10.1038/nature13904 – volume: 391 start-page: 748 issue: 10122 year: 2018 ident: 3954_CR14 publication-title: Lancet (Lond, Engl) doi: 10.1016/S0140-6736(17)33297-X – volume: 30 start-page: 644 issue: 4 year: 2019 ident: 3954_CR8 publication-title: Ann Oncol doi: 10.1093/annonc/mdz037 – ident: 3954_CR27 – volume: 5 start-page: 43 year: 2017 ident: 3954_CR34 publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0242-5 – volume: 36 start-page: 62 issue: 5_Suppl year: 2018 ident: 3954_CR25 publication-title: J Clin Oncol doi: 10.1200/jco.2018.36.5_suppl.62 – volume: 8 start-page: 593 issue: 3 year: 2016 ident: 3954_CR7 publication-title: MAbs doi: 10.1080/19420862.2015.1136043 – volume: 95 start-page: 386 issue: 4 year: 2014 ident: 3954_CR23 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.4 – volume: 95 start-page: 558 issue: 5 year: 2014 ident: 3954_CR18 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2014.24 – volume: 2 start-page: 542 issue: 7 year: 2004 ident: 3954_CR28 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/S1542-3565(04)00238-1 – volume: 53 start-page: 160 issue: 2 year: 2013 ident: 3954_CR17 publication-title: J Clin Pharmacol doi: 10.1177/0091270012445206 – ident: 3954_CR31 – volume: 18 start-page: 6580 issue: 24 year: 2012 ident: 3954_CR2 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-1362 – ident: 3954_CR4 – volume: 379 start-page: 2108 issue: 22 year: 2018 ident: 3954_CR16 publication-title: N Eng J Med doi: 10.1056/NEJMoa1809615 – ident: 3954_CR26 – volume: 44 start-page: 403 issue: 5 year: 2017 ident: 3954_CR20 publication-title: J Pharmacokinet Pharmacodyn doi: 10.1007/s10928-017-9528-y – volume: 101 start-page: 582 issue: 5 year: 2017 ident: 3954_CR22 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.628 – volume: 515 start-page: 563 issue: 7528 year: 2014 ident: 3954_CR3 publication-title: Nature doi: 10.1038/nature14011 – volume: 101 start-page: 201 year: 2018 ident: 3954_CR12 publication-title: Eur J Cancer doi: 10.1016/j.ejca.2018.06.031 – volume: 36 start-page: 3062 issue: 15 year: 2018 ident: 3954_CR32 publication-title: J Clin Oncol doi: 10.1200/JCO.2018.36.15_suppl.3062 – volume: 6 start-page: 58 issue: 1 year: 2017 ident: 3954_CR19 publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1002/psp4.12143 – volume: 24 start-page: 3292 issue: 14 year: 2018 ident: 3954_CR24 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-3662 – ident: 3954_CR5 – volume: 389 start-page: 255 issue: 10066 year: 2017 ident: 3954_CR13 publication-title: Lancet (Lond, Engl) doi: 10.1016/S0140-6736(16)32517-X – ident: 3954_CR30 – reference: 31630223 - Cancer Chemother Pharmacol. 2019 Dec;84(6):1153-1155 |
| SSID | ssj0004133 |
| Score | 2.534629 |
| Snippet | Purpose
To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell... To determine the exposure-response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung cancer... PurposeTo determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell lung... PURPOSE: To determine the exposure–response (ER) relationships between atezolizumab exposure and efficacy or safety in patients with advanced non-small cell... |
| SourceID | pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1257 |
| SubjectTerms | Adult Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - pharmacokinetics Bladder cancer Body weight Cancer Research carcinoma Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Transitional Cell - drug therapy Carcinoma, Transitional Cell - mortality Clinical Trials, Phase I as Topic Clinical Trials, Phase III as Topic Computer Simulation Datasets as Topic Dosage Dose-Response Relationship, Drug Drug Administration Schedule Drug development Female Humans Immunotherapy Infusions, Intravenous lung neoplasms Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Medicine Medicine & Public Health Models, Biological Monoclonal antibodies Monte Carlo Method Non-small cell lung carcinoma Oncology Original Original Article pharmacokinetics Pharmacology/Toxicology Randomized Controlled Trials as Topic Safety Survival Analysis Targeted cancer therapy Treatment Outcome Urologic Neoplasms - drug therapy Urologic Neoplasms - mortality Urothelial cancer Urothelial carcinoma |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BQYgLj_IKLWiQUC9spE3ijePeKtSKC9UKCuot8itlpd2k2uxWbX89Y-elbSkSnD2ObGec-SYz8w3ARzLZSmYJuanKipClNgolWa2Q9MNIFRcE6aVvNsGPj7PTUzFti8LqLtu9C0n6L3Vf7OajgOT6inCcCHpcdh8ekLnL3HX89v3nUA0ZNQ3kE8bCCR-ztlTmz8_YNEe3MObtVMkb8VJvho6e_t8GnsGTFnbiQaMnz-GeLbfh0dc2sL4Ne9OGwvpqhCdDRVY9wj2cDuTWVy_g8mDe_kK8sGgq96cBXXOHBbnDSAAYCbteV_PZ9Xoh1T7KEu2ldAzEWBXo2-6EDVerNWiW6zM0Q9YSzkokPIrnVb1adNXYWFufmv0Sfhwdnnz-ErbdG0JNGHNFR294QZ_SLBVSMKsFgQ8eGfJ3xpHh2kQ2s8Wk0IwABA0xrbkmF1lrVWgpzCR5BVtlVdo3gFKplKXKxoU2TNEBSsk4UywqMitVGgUQdS8x1y21ueuwMc97UmZ_9jlNzf3Z51kAn_o55w2xx1-ldzvdyNtLXudxLBxbIhNJAB_6YbqeLuYiS1utvQwBJh7H_G6ZxFmdiUPeAbxu1K1fEo0xF_wOgG8oYi_g6ME3R8rZL08Tnjpqfjdz1KnjsPS7d_r238R34HHsNNon-OzC1mq5tu_gob5Yzerle38xfwON2zUq priority: 102 providerName: Springer Nature |
| Title | Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting |
| URI | https://link.springer.com/article/10.1007/s00280-019-03954-8 https://www.ncbi.nlm.nih.gov/pubmed/31542806 https://www.proquest.com/docview/2294759493 https://www.proquest.com/docview/2296137227 https://www.proquest.com/docview/3153856153 https://pubmed.ncbi.nlm.nih.gov/PMC6820606 |
| Volume | 84 |
| WOSCitedRecordID | wos000497443600012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1432-0843 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004133 issn: 0344-5704 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwED-xDSFe-BhfhVEZCe2FRjSJG8e8oDFt4oWqGgP1LfJXoFKblKadtv31nB0nUZm2F14iRbYlW3fn-9l3_h3Ae3TZUqQxHlOl4QFNTBgI9FoB6ocWMsoR0gtXbIKNx-l0yif-wq3yaZXNnug2al0qe0f-MYq4paajPP68_BPYqlE2uupLaOzAXhgNqTXM9LhL8cANui6PTGkwYkPqH824p3MupogHaR4MY46TS7cd0w20eTNp8p_IqXNIp4__dylP4JGHouSo1p2ncM8U-_Dgmw-278PhpKa1vhqQ8-6VVjUgh2TSEV5fPYPLo7m_VrwwRJf29oHYgg8LPCITBMUE8ex1OZ9dbxZCfiKiIOZSWFZiUubEleIJav5Wo4lebX4R3WUykVlBEKOSZVmtF80LbVIZl679HH6cnpwffw18RYdAIe5coxA0y3F7TRMuODWKIyBhocYz0DDUTOnQpCYf5YoiqMAmqhRTeGxWSuZKcD2KX8BuURbmFRAhZUITaaJcaSpRjkJQRiUN89QImYQ9CBtxZsrTnduqG_OsJWp2KpDh0MypQJb24EM7ZlmTfdzZ-6ARb-YNv8o62fbgXduMJmvjMKIw5cb1QRDFoojd3ie2nmhk0XgPXtaK104J26gNiPeAbalk28FShm-3FLPfjjo8sXT9duSgUd5u6rev9PXdK30DDyNrSC7J5wB216uNeQv31cV6Vq36sMOmzH3TvjPPPux9ORlPzvDv7PvPv4saQ3U |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB5VBUEvPAoUQ4FFgl6IRWxvvDYSQhVQtWob5RCk3My-DJESO8RJafqj-I3Mrl8KVXvrgfPuyvZ6Xrsz830Ab9BlCx4FeEwVOnZpqD2Xo9dyUT4UF36KIT23ZBOs349Go3iwAX_qXhhTVlnbRGuoVS7NHfl7348NNB2Ng0-zX65hjTLZ1ZpCoxSLY736jUe24uPRF_y_b33_4Ovw86FbsQq4EmOfhdtjiqWo4lEY85hqGaNTZJ7COLzrKSaVpyOd9lJJ0bHhEJWSSTy6SSlSyWNlWCLQ5N9CO85MCRkbsbYP0yup6wNK8TFdWjXp2FY9m8PEg3vsdoMYNyNad4SXotvLRZr_ZGqtAzy4_79t3QO4V4XaZL_UjYewobNtuHNaFRNsw96ghO1edciw7UIrOmSPDFpA79UjON-fVNemZ5qo3NyuEENoMdVZQTDoJxivX-ST8cVyysUHwjOiz7lBXSZ5SizVkFvi02pF1Hz5g6i2UouMM4IxOJnlxWJad6CTQtty9Mfw7UY26AlsZnmmnwLhQoQ0FNpPpaIC5YZzyqigXhppLkLPAa8Wn0RWcO6GVWSSNEDUVuQSXJpYkUsiB941a2YlmMm1s3drcUoqw1YkrSw58LoZRpNk8kw80_nSzsEgkfk-u3pOYDxtz5w2HNgpBb15JRyjJuHvAFtTgWaCgURfH8nGPy00emjoCMzKTq0s7atf_aXPrv_SV3D3cHh6kpwc9Y-fw5ZvlNgWNO3C5mK-1C_gtjxbjIv5S2sOCHy_aSX6C74xm_0 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB5VBVVcChRoDQUWCXohVmN747WREKooEVUhyqFIuZl9GSIldoiT0vSn8euYXb8UqvbWA-fdle31PHdnvg_gNbpswaMA01ShY5eG2nM5ei0X5UNx4acY0nNLNsEGg2g0iocb8KfuhTFllbVNtIZa5dKckR_6fmyg6WgcHKZVWcTwuP9h9ss1DFLmprWm0yhF5FSvfmP6Vrw_OcZ__cb3-5_OPn52K4YBV2IctHB7TLEU1T0KYx5TLWN0kMxTGJN3PcWk8nSk014qKTo5HKJSMolpnJQilTxWhjECzf8dFgTM0EawEWt7Mr2Sxj6gFB_TpVXDjm3bs_eZmMTHbjeIcWOidad4JdK9WrD5z62tdYb9-__zNj6A7SoEJ0elzjyEDZ3twNbXqshgBw6GJZz3qkPO2u60okMOyLAF-l49goujSXWceq6Jys2pCzFEF1OdFQSTAYJx_GU-GV8up1y8Izwj-oIbNGaSp8RSELklbq1WRM2XP4hqK7jIOCMYm5NZXiymdWc6KbQtU38M325lg57AZpZneg8IFyKkodB-KhUVKEOcU0YF9dJIcxF6Dni1KCWygnk3bCOTpAGotuKX4NLEil8SOfC2WTMrQU5unL1fi1ZSGbwiaeXKgVfNMJoqc__EM50v7RwMHpnvs-vnBMYD90wW4sBuKfTNK-EYNYUADrA1dWgmGKj09ZFs_NNCpoeGpsCs7NSK07769V_69OYvfQlbqDvJl5PB6TO45xt9tnVO-7C5mC_1c7grzxfjYv7CWgYC329bh_4C9_2ksQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alternative+dosing+regimens+for+atezolizumab%3A+an+example+of+model-informed+drug+development+in+the+postmarketing+setting&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=Morrissey%2C+Kari+M&rft.au=Marchand%2C+Mathilde&rft.au=Patel%2C+Hina&rft.au=Zhang%2C+Rong&rft.date=2019-12-01&rft.pub=Springer+Nature+B.V&rft.issn=0344-5704&rft.eissn=1432-0843&rft.volume=84&rft.issue=6&rft.spage=1257&rft.epage=1267&rft_id=info:doi/10.1007%2Fs00280-019-03954-8&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon |